The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Waldenström’s macroglobulinemia: a link between institution visited and survival
Waldenström macroglobulinemia (WM) is a rare B-cell malignancy, and practicing hematologists and oncologists may rarely treat these patients. Here, Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, raises the question: does a patient’s outcome depend on the institution visited? Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Ansell reveals a correlation between these factors, before stressing the importance of seeking out expertise and going to a center that sees a lot of patients.
